Androgen Deprivation Therapy, ADT, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent the prostate cancer cells from growing
About the Study
Participants were randomly assigned to standard of care (ADT alone or with Taxotere), standard of care plus radiotherapy, standard of care plus Abiraterone plus Prednisone, or standard of care plus radiotherapy plus Abiraterone.
In the overall population, patients assigned to receive Abiraterone had longer time until their disease had progressed and longer survival than patients who did not receive Abiraterone.
In the ADT with Taxotere population, the outcomes were similar.
In the ADT with Taxotere population, harsh side effects occurred in 63% patients who received Abiraterone and in 52% of the patients who did not
Hypertension had the largest difference in occurrence: 22% patients and 13%, respectively.
Combining ADT, Taxotere, and Abiraterone in newly diagnosed metastatic CSPC improved Survival and time until the disease had progressed with a modest increase in toxicity, mostly hypertension.
This triplet therapy could become a standard of care for these patients.
This phase III trial assessed the efficacy and safety of Abiraterone plus Prednisone, with or without radiotherapy, in addition to standard of care (ADT) alone or with Taxotere in 1172 patients with newly diagnosed metastatic CSPC.
ADT, Taxotere, and Abiraterone plus Prednisone, improved Survival and time until the disease had progressed. Without a substantial increase in toxicity compared with the standard of care.
This triple therapy should be considered for patients with newly diagnosed metastatic CSPC with a high metastatic burden who are fit for treatment with Taxotere.
Talk to us so see if we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039